Silibor 35
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Silibor 35 is a hepatoprotective agent of plant origin.
Release form and composition
Dosage form - coated tablets: biconvex, from orange to brownish-orange color, on the surface there may be inclusions and marbling of color; on the cross section, two layers are visible (10 pcs. in blisters, 3 or 8 blisters in a box; 25 pcs. in blisters, 1 blister in a box).
1 tablet contains:
- active substance: silymarin - 35 mg;
- auxiliary components: lactose monohydrate, sodium starch glycolate (type A), potato starch, hypromellose, calcium stearate, titanium dioxide (E 171) and dye Sunset Yellow FCF (E 110).
Indications for use
Silibor 35 is used for the maintenance therapy of chronic inflammatory diseases and liver cirrhosis.
Contraindications
- acute poisoning of various etiologies;
- hereditary galactose intolerance, lactase deficiency, glucose / galactose malabsorption;
- children under 5 years old;
- hypersensitivity to the components of the drug.
Method of administration and dosage
Silibor 35 should be taken orally, before meals, swallowing tablets whole and drinking plenty of water.
Adults and adolescents over 12 years old are prescribed 1–2 tablets 3 times a day, children 5–12 years old - 3 mg / kg / day in 2–3 doses.
The doctor determines the duration of therapy individually for each patient, depending on the type and severity of the disease.
The average duration of the course of treatment is 3 months.
Side effects
Silibor 35 is generally well tolerated. In rare cases, the following side effects occur:
- allergic reactions: itching, skin rashes, increased alopecia;
- digestive system: diarrhea, dyspepsia, nausea;
- others: shortness of breath, increased urine output, increased existing vestibular disorders.
The resulting side effects are transient and disappear on their own (without taking special measures) after the drug is discontinued.
special instructions
Silymarin can have an estrogen-like effect, and therefore Silibor 35 should be used with caution in patients with diseases accompanied by hormonal disorders - endometriosis; uterine myoma; carcinoma of the uterus, ovaries and breast; carcinoma of the prostate. In these cases, a doctor's consultation is necessary.
Treatment will be effective only if you follow a diet and abstain from drinking alcohol.
With the development of jaundice, you should consult a doctor for correction of therapy.
There are no data on the effectiveness and safety of using Silibor 35 during pregnancy and during lactation.
The drug does not affect the speed of reactions and the ability to concentrate. Patients with vestibular disorders, due to the risk of their intensification during treatment, should be careful when driving and performing other potentially dangerous types of work.
Drug interactions
Silymarin can reduce the effectiveness of oral contraceptives and drugs used for estrogen replacement therapy.
By inhibiting the cytochrome P450 system, Silibor 35 can enhance the effects of the following drugs: diazepam, vinblastine, ketoconazole, alprazolam, lovastatin.
Terms and conditions of storage
Store in original packaging out of reach of children at temperatures up to 25 ° C.
Shelf life is 2 years.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
